These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33817540)

  • 1. Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists.
    Yoshida Y; Yoshida R; Shibuta K; Ozeki Y; Okamoto M; Gotoh K; Masaki T; Shibata H
    J Endocr Soc; 2021 Apr; 5(4):bvab020. PubMed ID: 33817540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.
    Yoshida Y; Fujiwara M; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Iwamoto M; Mori Y; Nagai S; Matsuda N; Noguchi T; Okamoto M; Gotoh K; Masaki T; Shibata H
    Hypertens Res; 2024 Jan; 47(1):157-167. PubMed ID: 37717115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment.
    Velema M; Dekkers T; Hermus A; Timmers H; Lenders J; Groenewoud H; Schultze Kool L; Langenhuijsen J; Prejbisz A; van der Wilt GJ; Deinum J;
    J Clin Endocrinol Metab; 2018 Jan; 103(1):16-24. PubMed ID: 29099925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective Observational Study of Factors Affecting the Change in Quality of Life in Patients With Primary Aldosteronism After Treatment.
    Yu J; Xu B; Ma G; Liu Y; Yang Y; Xu J; Sun M
    Endocr Pract; 2024 Jan; 30(1):19-24. PubMed ID: 37858723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone.
    Künzel HE; Apostolopoulou K; Pallauf A; Gerum S; Merkle K; Schulz S; Fischer E; Brand V; Bidlingmaier M; Endres S; Beuschlein F; Reincke M
    J Psychiatr Res; 2012 Dec; 46(12):1650-4. PubMed ID: 23017810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Front Endocrinol (Lausanne); 2021; 12():625457. PubMed ID: 33841329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative mineralocorticoid receptor antagonist reduces postoperative hyperkalaemia in patients with Conn syndrome.
    Zhang J; Libianto R; Lee JC; Grodski S; Shen J; Fuller PJ; Yang J
    Clin Endocrinol (Oxf); 2022 Jan; 96(1):40-46. PubMed ID: 34743353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adrenal Ablation Versus Mineralocorticoid Receptor Antagonism for the Treatment of Primary Aldosteronism: A Single-Center Prospective Cohort Study.
    Zhou Y; Liu Q; Wang X; Wan J; Liu S; Luo T; He P; Hou J; Pu J; Wang D; Liang D; Yang Y; Wang P
    Am J Hypertens; 2022 Dec; 35(12):1014-1023. PubMed ID: 36205513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salt intake in mineralocorticoid receptor antagonist-treated primary aldosteronism: foe or ally?
    Fountoulakis S; Papanastasiou L; Voulgaris N; Kounadi T; Markou A; Chrousos GP; Piaditis G
    Hormones (Athens); 2020 Jun; 19(2):223-232. PubMed ID: 31863347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life in primary aldosteronism: A prospective observational study.
    Buffolo F; Cavaglià G; Burrello J; Amongero M; Tetti M; Pecori A; Sconfienza E; Veglio F; Mulatero P; Monticone S
    Eur J Clin Invest; 2021 Mar; 51(3):e13419. PubMed ID: 32997795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid receptor antagonist treatment improved arterial stiffness in patients with primary aldosteronism: a cohort study compared with adrenalectomy.
    Liao CW; Lin YT; Tsai CH; Chang YY; Chen ZW; Lu CC; Pan CT; Chang CC; Lee BC; Chiu YW; Huang WC; Huang KH; Lai TS; Hung CS; Wu VC; Wu XM; Lin YH;
    Ther Adv Chronic Dis; 2023; 14():20406223221143233. PubMed ID: 36687666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically.
    Ahmed AH; Gordon RD; Sukor N; Pimenta E; Stowasser M
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2904-11. PubMed ID: 21778218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
    Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
    J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Dosage of MRA Improves BP and Urinary Albumin Excretion in Primary Aldosteronism With Suppressed Plasma Renin.
    Saiki A; Otsuki M; Tamada D; Kitamura T; Mukai K; Yamamoto K; Shimomura I
    J Endocr Soc; 2022 Jan; 6(1):bvab174. PubMed ID: 34909517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
    Riester A; Reincke M
    Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of unilateral adrenalectomy on the quality of life of patients with lateralized primary aldosteronism.
    Citton M; Viel G; Torresan F; Rossi GP; Iacobone M
    BMC Surg; 2019 Apr; 18(Suppl 1):105. PubMed ID: 31074381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism.
    Nanba AT; Wannachalee T; Shields JJ; Byrd JB; Rainey WE; Auchus RJ; Turcu AF
    J Clin Endocrinol Metab; 2019 Feb; 104(2):487-492. PubMed ID: 30239792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism.
    Park KS; Kim JH; Yang YS; Hong AR; Lee DH; Moon MK; Choi SH; Shin CS; Kim SW; Kim SY
    Endocr J; 2017 Jun; 64(6):623-632. PubMed ID: 28458337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administrative data on diagnosis and mineralocorticoid receptor antagonist prescription identified patients with primary aldosteronism in Taiwan.
    Wu VC; Hu YH; Wu CH; Kao CC; Wang CY; Yang WS; Lee HH; Chang YS; Lin YH; Wang SM; Chen L; Wu KD;
    J Clin Epidemiol; 2014 Oct; 67(10):1139-49. PubMed ID: 25034196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Different Treatment Strategies on New-Onset Atrial Fibrillation Among Patients With Primary Aldosteronism: A Nationwide Longitudinal Cohort-Based Study.
    Pan CT; Liao CW; Tsai CH; Chen ZW; Chen L; Hung CS; Liu YC; Lin PC; Chang CC; Chang YY; Wu VC; Lin YH;
    J Am Heart Assoc; 2020 Mar; 9(5):e013699. PubMed ID: 32070205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.